专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6028032A 1,3-oxazin-4-one derivatives as herbicides 失效
标题翻译： 1,3-恶嗪-4-酮衍生物作为除草剂
公开(公告)号：US6028032A
公开(公告)日：2000-02-22
申请号：US981569
申请日：1998-04-13
申请人： Michael Colin Cramp , Yoshihiro Usui , Keiichi Hayashizaki
发明人： Michael Colin Cramp , Yoshihiro Usui , Keiichi Hayashizaki
IPC分类号： A01N43/86 , C07D265/06 , C07F7/18
CPC分类号： C07D265/06 , A01N43/86
摘要： 1,3-oxazin-4-ones of formula (I), ##STR1## wherein R.sup.1 represents phenyl optionally substituted; R.sup.2 represents: a straight- or branched-chain alkyl having from one to ten carbon atoms which is substituted by one or more groups R.sup.8 which may be the same or different; a straight- or branched-chain optionally halogenated alkenyl or alkynyl group having up to ten carbon atoms; or a group selected from cyano, --CHO, --COR.sup.7, --CO.sub.2 H, --CO.sub.2 R.sup.7, --COSR.sup.7, --CONR.sup.9 R.sup.10, --CH.dbd.NOH, --CH.dbd.NOR.sup.7, --CH.dbd.NOCOR.sup.7, --CH.dbd.NNR.sup.9 R.sup.10, --CH.sub.2 CN, --CH.sub.2 NO.sub.2 and oxiranyl; R.sup.3 represents phenyl optionally substituted or R.sup.3 represents a first five to seven membered heteroaromatic ring; said first ring being optionally fused and said first ring being linked to the nitrogen atom of the group NR.sup.6 via one of the ring carbon atoms; R.sup.4 and R.sup.5 independently represent lower alkyl; W represents --NR.sup.6 --; R.sup.6 represents hydrogen, lower alkyl, haloalkyl, alkenyl, alkynyl, --COR.sup.7 or --CO.sub.2 R.sup.7 ; and their use as herbicides.
摘要翻译： PCT No.PCT / EP96 / 02616 371日期：1998年4月13日 102（e）1998年4月13日PCT PCT 1996年6月18日PCT公布。出版物WO97 / 00865 日本1991年1月9日公开了式（I）的1,3-二嗪-4-酮，其中R 1表示任选取代的苯基; R2表示：具有1至10个碳原子的直链或支链烷基，其被一个或多个可以相同或不同的基团R 8取代; 具有至多10个碳原子的直链或支链任选卤代的烯基或炔基; 或选自氰基，-CHO，-COR 7，-CO 2 H，-CO 2 R 7，-COSR 7，-CONR 9 R 10，-CH = NOH，-CH = NOR 7，-CH = NOCOR 7，-CH = NNR 9 R 10，-CH 2 CN，-CH 2 NO 2 和环氧乙烷基; R3代表任意取代的苯基或R3代表第一个五至七元杂芳环; 所述第一环任选地稠合，并且所述第一环通过环碳原子之一与NR6的氮原子连接; R4和R5独立地表示低级烷基; W代表-NR6-; R6代表氢，低级烷基，卤代烷基，烯基，炔基，-COR7或-COO2R7; 及其作为除草剂的用途。

2. 发明授权

US08173812B2 Quinolines and their therapeutic use 有权
标题翻译：喹啉及其治疗用途
公开(公告)号：US08173812B2
公开(公告)日：2012-05-08
申请号：US12531935
申请日：2008-04-03
申请人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
发明人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
IPC分类号： C07D215/38 , A61K31/04
CPC分类号： C07D401/10 , C07D215/227 , C07D215/233 , C07D413/10 , C07D417/10
摘要： Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1-C6 alkyl or C3-C6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(═O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.
摘要翻译：式（I）化合物是可用于治疗例如哮喘和COPD的CRTH2配体，其中：R1是卤素或氰基; R2是氢或甲基; R 3和R 4独立地为-OR 6，C 1 -C 6烷基或C 3 -C 6环烷基，后两个基团任选被一个或多个卤素原子取代; R5是氢或卤素; R6是C1-C6烷基或C3-C6环烷基，其任一个任选被一个或多个卤素原子取代; X是-CH 2 - ， - S-或-O-; Y和Y1中的一个是氢，另一个是选自本说明书中提到的那些的OR 6，-C（= O）R 7，NR 8 SO 2 R 6或杂环基; R6，R7和R8如说明书中所定义。

3. 发明申请

US20090163534A1 Indolizine Derivatives 审中-公开
标题翻译：中氮衍生物
公开(公告)号：US20090163534A1
公开(公告)日：2009-06-25
申请号：US11993412
申请日：2006-06-26
申请人： George Hynd , Nicholas Charles Ray , Harry Finch , David Middlemiss , Michael Colin Cramp , Paul Matthew Blaney , Karen Williams , Yan Griffon , Trevor Keith Harrison , Peter Crackett
发明人： George Hynd , Nicholas Charles Ray , Harry Finch , David Middlemiss , Michael Colin Cramp , Paul Matthew Blaney , Karen Williams , Yan Griffon , Trevor Keith Harrison , Peter Crackett
IPC分类号： A61K31/437 , C07D221/04 , A61P29/00
CPC分类号： C07D471/04
摘要： Compounds of formula (I) are ligands of the CRTH2 receptor and are useful in the treatment of respiratory disease: Formula (I) wherein R1, R2, R3 and R4 each independently are hydrogen, C1C6alkyl, fully or partially fluorinated C1C6alkyl, halo, —S(O)nR10, —SO2N(R10)2, —N(R10)2, —C(O)N(R10)2, —NR10C(O)R9, —CO2R10, —C(O)R9, —NO2, —CN or —OR11; wherein each R9 is independently C1C6alkyl, aryl, heteroaryl; R10 is independently hydrogen, C1C6alkyl, aryl, or heteroaryl; R11 is hydrogen, C1C6alkyl, fully or partially fluorinated C1C6alkyl or a group —SO2R9; n is 0, 1 or 2; R5 is C1C6alkyl, fully or partially fluorinated C1C6alkyl. C1C6alkenyl, C1C6alkynyl, optionally substituted aryl, or optionally substituted heteroaryl; R6 is hydrogen, C1C6alkyl or fully or partially fluorinated C1C6alkyl; R7 and R5 are independently hydrogen or C1C6alkyl, or R7 and R5 together with the atom to which they are attached form a cycloalkyl group; and X is —CHR6—, —S(O)n—, —NR6SO2— or —SO2NR6— wherein n is 0, 1 or 2.
摘要翻译：式（I）化合物是CRTH2受体的配体，可用于治疗呼吸系统疾病：其中R 1，R 2，R 3和R 4各自独立地为氢，C 1 -C 6烷基，完全或部分氟化的C 1 -C 6烷基，卤素， S（O）nR10，-SO2N（R10）2，-N（R10）2，-C（O）N（R10）2，-NR10C（O）R9，-CO2R10，-C（O），-CN或-OR11; 其中每个R 9独立地为C 1 -C 6烷基，芳基，杂芳基; R 10独立地是氢，C 1 -C 6烷基，芳基或杂芳基; R 11是氢，C 1 -C 6烷基，完全或部分氟化的C 1 -C 6烷基或基团-SO 2 R 9; n为0,1或2; R5是C1C6烷基，完全或部分氟化的C1C6烷基。 C 1 -C 6烯基，C 1 -C 6炔基，任选取代的芳基或任选取代的杂芳基; R6是氢，C1C6烷基或完全或部分氟化的C 1 -C 6烷基; R 7和R 5独立地为氢或C 1 -C 6烷基，或者R 7和R 5与它们所连接的原子一起形成环烷基; 且X为-CHR 6 - ， - S（O）n - ， - NR 6 SO 2 - 或-SO 2 NR 6 - ，其中n为0,1或2。

4. 发明申请

US20090156600A1 Quinolines and Their Therapeutic Use 有权
标题翻译：喹啉及其治疗用途
公开(公告)号：US20090156600A1
公开(公告)日：2009-06-18
申请号：US12066603
申请日：2006-09-29
申请人： Michael Colin Cramp , Rosa Arienzo , George Hynd , Peter Crackett , Yann Griffon , Trevor Keith Harrison , Nicholas Charles Ray , Harry Finch , John Gary Montana
发明人： Michael Colin Cramp , Rosa Arienzo , George Hynd , Peter Crackett , Yann Griffon , Trevor Keith Harrison , Nicholas Charles Ray , Harry Finch , John Gary Montana
IPC分类号： A61K31/5377 , C07D215/233 , A61P11/06 , C07D413/14 , A61K31/47
CPC分类号： C07D215/233 , A61K31/47 , C07D215/12 , C07D215/18 , C07D215/20 , C07D215/227 , C07D215/36 , C07D215/48 , C07D401/04 , C07D401/10 , C07D401/12
摘要： Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component; in which: R1, R2, R3, R4 and R5 are independently hydrogen, C1-C6alkyl, C1-C6-fluoroalkyl, cyclopropyl, halo, —S(O)nR6, —SO2NR7R8, —NR7R8, —NR7C(O)R6, —CO2R7, —C(O)NR7R8, —C(O)R76, —NO2, —CN or a group —OR9; wherein each R6 is independently C1-C6alkyl, C1-C6-fluoroalkyl, cycloalkyl, aryl, or heteroaryl; R7, R8 are independently C1-C6alkyl, C1-C6-fluoroalkyl, cycloalkyl, cycloalkyl-(C1-C6alkyl)-, aryl, heteroaryl or hydrogen; R9 is hydrogen, C1-C6alkyl, C1-C6-fluoroalkyl, cycloalkyl, cylcoalkyl-(C1-C6alkyl)-, or a group —SO2R6; A is —CHR10—, —C(O)—, —S(O)n—, —O—, or —NR10— wherein n is an integer from 0-2 and R10 is hydrogen C1-C3alkyl, or C1-C6-fluoroalkyl group; B is a direct bond, or a divalent radical selected from —CH2—, —CH2CH2—, —CHR11—, —CR11R12—, —CH2CHR11—, CH2CR11R12—, —CHR11CHR12—, and divalent radicals of formula —(CR11R12)p-Z- wherein Z is attached to the ring carrying R1, R2 and R3; wherein R11 is C1-C3alkyl, cyclopropyl, C1-C6-fluoroalkyl; R12 is methyl or fluoromethyl; p is independently 1 or 2; and Z is —O—, —NH—, or —S(O)n—, wherein n is an integer from 0-2; X is a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, or sulfonic acid group, or a group of formula C(═O)NHSO2R6 or SO2NHC(═O)R6; and Y is aryl, heteroaryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group.
摘要翻译：式[1]化合物是CRTH2拮抗剂，可用于治疗具有炎性成分的病症; 其中：R1，R2，R3，R4和R5独立地是氢，C1-C6烷基，C1-C6-氟烷基，环丙基，卤素，-S（O）nR6，-SO2NR7R8，-NR7R8，-NR7C（O） -C（O）NR 7 R 8，-C（O）R 76，-NO 2，-CN或-OR 9基团; 其中每个R 6独立地为C 1 -C 6烷基，C 1 -C 6 - 氟烷基，环烷基，芳基或杂芳基; R 7，R 8独立地是C 1 -C 6烷基，C 1 -C 6氟代烷基，环烷基，环烷基 - （C 1 -C 6烷基） - ，芳基，杂芳基或氢; R 9是氢，C 1 -C 6烷基，C 1 -C 6 - 氟代烷基，环烷基，环烷基 - （C 1 -C 6烷基） - 或-SO 2 R 6基团; A是-CHR 10 - ， - C（O） - ， - S（O）n - ， - O-或-NR 10 - ，其中n是0-2的整数，R 10是氢C1-C3烷基或C1-C6 氟烷基或选自-CH 2 - ， - CH 2 CH 2 - ， - CHR 11 - ， - CR 11 R 12 - ， - CH 2 CHR 11 - ，CH 2 CR 11 R 12 - ， - CHR 11 CHR 12 - - 的二价基团和式 - （CR11R12）pZ- 其中Z连接到携带R1，R2和R3的环上; 其中R11是C1-C3烷基，环丙基，C1-C6-氟代烷基; R12是甲基或氟甲基; p独立地为1或2; 和Z是-O - ， - NH-或-S（O）n - ，其中n是0-2的整数; X是羧酸，四唑，3-羟基异恶唑，异羟肟酸，次膦酸盐，膦酸盐，膦酰胺或磺酸基，或式C（-O）NHSO 2 R 6或SO 2 NHC（-O）R 6的基团; 并且Y是芳基，杂芳基，芳基稠合 - 杂环烷基，杂芳基 - 稠合 - 环烷基，杂芳基 - 稠合 - 杂环烷基或芳基稠合 - 环烷基。

5. 发明申请

US20120184579A1 Quinolines and Their Therapeutic Use 有权
标题翻译：喹啉及其治疗用途
公开(公告)号：US20120184579A1
公开(公告)日：2012-07-19
申请号：US13435242
申请日：2012-03-30
申请人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
发明人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
IPC分类号： A61K31/4709 , C07D413/10 , C07D215/22 , C07D417/10 , A61P37/08 , A61P11/06 , A61P11/00 , A61P17/06 , A61P1/00 , A61P17/00 , C07D401/10 , A61K31/47
CPC分类号： C07D401/10 , C07D215/227 , C07D215/233 , C07D413/10 , C07D417/10
摘要： Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6alkyl or C3-C6cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(═O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.
摘要翻译：式（I）化合物是可用于治疗例如哮喘和COPD的CRTH2配体，其中：R1是卤素或氰基; R2是氢或甲基; R 3和R 4独立地为-OR 6，C 1 -C 6烷基或C 3 -C 6环烷基，后两个基团任选被一个或多个卤素原子取代; R5是氢或卤素; R6是C1C6烷基或C3-C6环烷基，其中任一个任选被一个或多个卤素原子取代; X是-CH 2 - ， - S-或-O-; Y和Y1中的一个是氢，另一个是选自本说明书中提到的那些的OR 6，-C（= O）R 7，NR 8 SO 2 R 6或杂环基; R6，R7和R8如说明书中所定义。

6. 发明申请

US20100137300A1 Indolizine Acetic Acid Derivatives as CRTH2 Antagonists 审中-公开
标题翻译： Indolizine乙酸衍生物作为CRTH2拮抗剂
公开(公告)号：US20100137300A1
公开(公告)日：2010-06-03
申请号：US12530929
申请日：2007-03-21
申请人： George Hynd , Nicholas Charles Ray , Harry Finch , John Gary Montana , Michael Colin Cramp , Trevor Keith Harrison , Rosa Arienzo , Paul Blaney , Yann Griffon , David Middlemiss
发明人： George Hynd , Nicholas Charles Ray , Harry Finch , John Gary Montana , Michael Colin Cramp , Trevor Keith Harrison , Rosa Arienzo , Paul Blaney , Yann Griffon , David Middlemiss
IPC分类号： A61K31/5377 , A61K31/435 , A61K31/4709 , C07D413/12 , C07D221/04 , C07D215/14 , A61P1/00 , A61P11/06 , A61P11/00 , A61P1/04
CPC分类号： C07D471/04
摘要： The specific compounds of this list: {7-cyano-2-methyl-1-[4-(morpholine-4-sutfonyl)benzyl]indolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylbenzyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro4-(morpholine-4-sulfonyl)benzyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-(3-chloro-4-ethanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-3-yl}acetic acid, {1-[3-chloro-4-(morpholine-4-sutfonyl)phenylsutfanyl]-7-cyano-2-methylindolizin-3-yl}acetic acid, {7-cyano-1-(6-fluoroquinolin-2-ylmethyl)-2-methylindolizin-3-yl}acetic acid are ligands of the CRTH2 receptor and are useful in the treatment of respiratory diseases.
摘要翻译：该列表的具体化合物：{7-氰基-2-甲基-1- [4-（吗啉-4-磺酰基）苄基]中氮茚-3-基}乙酸，{1-（3-氯-4-乙磺酰基苄基）-7-氰基-2-甲基吲哚啉-3-基}乙酸{1- [3-氯-4-（吗啉-4-磺酰基）苄基] -7-氰基-2-甲基吲哚啉-3-基}乙酸， {1-（3-氯-4-乙磺酰基苯基硫烷基）-7-氰基-2-甲基吲哚啉-3-基}乙酸{1- [3-氯-4-（吗啉-4-磺基）苯基f烷基] 氰基-2-甲基吲哚啉-3-基}乙酸，{7-氰基-1-（6-氟喹啉-2-基甲基）-2-甲基吲哚啉-3-基}乙酸是CRTH2受体的配体，可用于治疗呼吸系统疾病。

7. 发明授权

US6046135A 1,3-oxazin-4-one derivatives as herbicides 失效
标题翻译： 1,3-恶嗪-4-酮衍生物作为除草剂
公开(公告)号：US6046135A
公开(公告)日：2000-04-04
申请号：US77745
申请日：1998-09-02
申请人： Michael Colin Cramp , Yoshihiro Usui , Sachio Kudo
发明人： Michael Colin Cramp , Yoshihiro Usui , Sachio Kudo
IPC分类号： A01N43/86 , C07D265/06 , C07D413/04 , C07D413/06 , C07D417/06
CPC分类号： C07D413/04 , A01N43/86 , C07D265/06 , C07D413/06
摘要： 1,3-Oxazin-4-one derivatives of formula (I): ##STR1## wherein Q represents --C(.dbd.O)--, --CH(OH)-- or --C(OR.sup.11)(OR.sup.11)--, in which R.sup.11 represents lower alkyl; or the two groups --OR.sup.11, together with the carbon atom to which they are attached, form a five or six membered cyclic ketal group; and their use as herbicides.
摘要翻译： PCT No.PCT / EP96 / 05404 Sec。 371日期：1998年9月2日 102（e）1998年9月2日PCT 1996年12月4日PCT PCT。公开号WO97 / 21688 日期：19,1971年3-式（I）的恶嗪-4-酮衍生物：其中Q表示-C（= O） - ， - CH（OH） - 或-C（OR 11）（OR 11）其中R11表示低级烷基; 或两个基团-OR 11与它们所连接的碳原子一起形成五或六元环缩酮基团; 及其作为除草剂的用途。

8. 发明申请

US20100144787A1 Quinolines and Their Therapeutic Use 有权
标题翻译：喹啉及其治疗用途
公开(公告)号：US20100144787A1
公开(公告)日：2010-06-10
申请号：US12531935
申请日：2008-04-03
申请人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
发明人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
IPC分类号： A61K31/4709 , C07D215/233 , C07D215/227 , C07D215/12 , A61P11/06 , A61P11/08 , A61P11/16 , A61P11/02
CPC分类号： C07D401/10 , C07D215/227 , C07D215/233 , C07D413/10 , C07D417/10
摘要： Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6 alkyl or C3-C6 cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(═O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.
摘要翻译：式（I）化合物是可用于治疗例如哮喘和COPD的CRTH2配体，其中：R1是卤素或氰基; R2是氢或甲基; R 3和R 4独立地为-OR 6，C 1 -C 6烷基或C 3 -C 6环烷基，后两个基团任选被一个或多个卤素原子取代; R5是氢或卤素; R6是C1C6烷基或C3-C6环烷基，其任一个任选被一个或多个卤素原子取代; X是-CH 2 - ， - S-或-O-; Y和Y1中的一个是氢，另一个是选自本说明书中提到的那些的OR 6，-C（= O）R 7，NR 8 SO 2 R 6或杂环基; R6，R7和R8如说明书中所定义。

9. 发明申请

US20100144786A1 QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS 审中-公开
标题翻译：喹啉衍生物作为CRTH2受体配体
公开(公告)号：US20100144786A1
公开(公告)日：2010-06-10
申请号：US12531367
申请日：2007-03-29
申请人： Michael Colin Cramp , Rosa Arienzo , George Hynd , Peter Crackett , Yann Griffon , Trevor Keith Harrison , Nicholas Charles Ray , Harry Finch , John Gary Montana
发明人： Michael Colin Cramp , Rosa Arienzo , George Hynd , Peter Crackett , Yann Griffon , Trevor Keith Harrison , Nicholas Charles Ray , Harry Finch , John Gary Montana
IPC分类号： A61K31/47 , C07D215/233 , A61P17/02 , A61P11/06 , A61P37/06 , A61P17/06
CPC分类号： C07D215/233 , C07D215/20 , C07D215/227
摘要： Specific quinoline derivatives are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory component.
摘要翻译：特定的喹啉衍生物是可用于治疗具有炎性成分的病症的CRTH2拮抗剂。

10. 发明授权

US08394830B2 Quinolines and their therapeutic use 有权
标题翻译：喹啉及其治疗用途
公开(公告)号：US08394830B2
公开(公告)日：2013-03-12
申请号：US13435242
申请日：2012-03-30
申请人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
发明人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
IPC分类号： A61K31/04
CPC分类号： C07D401/10 , C07D215/227 , C07D215/233 , C07D413/10 , C07D417/10
摘要： Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6alkyl or C3-C6cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(═O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.
摘要翻译：式（I）化合物是可用于治疗例如哮喘和COPD的CRTH2配体，其中：R1是卤素或氰基; R2是氢或甲基; R 3和R 4独立地为-OR 6，C 1 -C 6烷基或C 3 -C 6环烷基，后两个基团任选被一个或多个卤素原子取代; R5是氢或卤素; R6是C1C6烷基或C3-C6环烷基，其中任一个任选被一个或多个卤素原子取代; X是-CH 2 - ， - S-或-O-; Y和Y1中的一个是氢，另一个是选自本说明书中提到的那些的OR 6，-C（= O）R 7，NR 8 SO 2 R 6或杂环基; R6，R7和R8如说明书中所定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式